Hutchmed (China)
HCM
Ermenegildo Zegna NV
ZGN
New Fortress Energy
NFE
Enerpac Tool
EPAC
eBay
EBAY
US Stock MarketDetailed Quotes
CARM Carisma Therapeutics
- 0.441
- -0.016-3.46%
Close Jan 17 16:00 ET
- 0.431
- -0.010-2.22%
Post 20:01 ET
18.40MMarket Cap-0.29P/E (TTM)
0.477High0.440Low162.82KVolume0.465Open0.457Pre Close74.20KTurnover0.54%Turnover RatioLossP/E (Static)41.75MShares2.77052wk High-1.66P/B13.32MFloat Cap0.38052wk Low--Dividend TTM30.22MShs Float51.357Historical High--Div YieldTTM8.08%Amplitude0.380Historical Low0.455Avg Price1Lot Size
Carisma Therapeutics News
Carisma Therapeutics | 8-K: Current report
Carisma Therapeutics | 8-K: Current report
Carisma Therapeutics | 3: Initial statement of beneficial ownership of securities-Officer McAndrew Natalie
Carisma Therapeutics | 8-K: Current report
Carisma Therapeutics | 8-K: Current report
Carisma Therapeutics | 10-Q: Q3 2024 Earnings Report
Carisma Therapeutics | 8-K: Carisma Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Carisma Therapeutics | 3: Initial statement of beneficial ownership of securities-Director Cheng Sohanya Roshan
Carisma Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Cheng Sohanya Roshan
Carisma Therapeutics | 8-K: Current report
Carisma Therapeutics | 8-K: Current report
Carisma Therapeutics | 10-Q: Q2 2024 Earnings Report
Carisma Therapeutics | 8-K: Carisma Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
Carisma Therapeutics | 8-K: Current report
Carisma Therapeutics | 8-K: Current report
Carisma Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Thorell Marella
Carisma Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Scadden David
Carisma Therapeutics | 3: Initial statement of beneficial ownership of securities-Director Thorell Marella
Carisma Therapeutics | 3: Initial statement of beneficial ownership of securities-Director Scadden David
Carisma Therapeutics | 8-K: Current report